INS and type 1 diabetes mellitus: Despite having a greater median (IQR) weight (81.8 [65.0-91.3] vs 67.7 [54.3-80.8] kg; P = .04), patients with SGLT2i DKA received a significantly lower insulin dose (intravenous and subcutaneous) in the first 24 hours of treatment compared with patients T1D DKA (median [IQR] dose: 44.0 [27.0-82.5] vs 87.0 [63.0-124.0] units; P = .01) (Figure).